DCIKKb / ICVS Tokyo Clinic, Hasumi International Research Foundation - LARVOL DELTA

From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. (PubMed, Curr Oncol) - "Molecular biology studies of uveal melanoma have resulted in the development of novel immunotherapy approaches including tebentafusp-a T cell-redirecting bispecific fusion protein...Current trials cover tumor-infiltrating lymphocytes (TIL), vaccination with IKKb-matured dendritic cells, or autologous dendritic cells loaded with autologous tumor RNA...Moreover, nanomedicine, especially miRNA approaches, are promising for future trials. Finally, theranostic radiopharmaceuticals enabling diagnosis and therapy with the same molecule bring hope to this research."

IO biomarker • Journal • Review • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Hasumi International Research Foundation | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Jan 2024 | Trial primary completion date: Jun 2022 ➔ Jan 2023

Enrollment closed • Trial completion date • Trial primary completion date • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • CD4

IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Hasumi International Research Foundation; Not yet recruiting ➔ Recruiting

Enrollment open • Melanoma • Oncology • Solid Tumor • Uveal Melanoma